Research Analysts Set Expectations for PMN FY2025 Earnings

Promis Neurosciences (NASDAQ:PMN) – Investment analysts at HC Wainwright lifted their FY2025 earnings estimates for shares of Promis Neurosciences in a research report issued on Monday, December 1st. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($22.12) for the year, up from their previous forecast of ($22.25). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Promis Neurosciences’ current full-year earnings is ($0.24) per share. HC Wainwright also issued estimates for Promis Neurosciences’ Q4 2025 earnings at ($4.22) EPS, Q1 2026 earnings at ($2.04) EPS, Q2 2026 earnings at ($1.54) EPS, Q3 2026 earnings at ($1.12) EPS, Q4 2026 earnings at ($0.91) EPS and FY2026 earnings at ($4.95) EPS.

Other research analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Promis Neurosciences in a research report on Wednesday, October 8th. Guggenheim lowered their price objective on shares of Promis Neurosciences from $150.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Finally, Wall Street Zen lowered shares of Promis Neurosciences to a “strong sell” rating in a research report on Saturday, November 29th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Promis Neurosciences has a consensus rating of “Moderate Buy” and a consensus target price of $72.67.

Promis Neurosciences Stock Performance

NASDAQ PMN opened at $7.63 on Wednesday. The stock has a 50-day simple moving average of $10.28 and a 200 day simple moving average of $12.37. Promis Neurosciences has a twelve month low of $6.27 and a twelve month high of $39.75. The stock has a market capitalization of $16.40 million, a PE ratio of -0.40 and a beta of -0.05.

Promis Neurosciences (NASDAQ:PMN) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($6.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.75) by ($2.25).

Institutional Trading of Promis Neurosciences

A number of institutional investors and hedge funds have recently modified their holdings of PMN. Citadel Advisors LLC lifted its position in Promis Neurosciences by 168.1% in the third quarter. Citadel Advisors LLC now owns 170,079 shares of the company’s stock worth $72,000 after purchasing an additional 106,650 shares during the period. Allostery Investments LP raised its stake in shares of Promis Neurosciences by 19.8% in the 1st quarter. Allostery Investments LP now owns 233,703 shares of the company’s stock valued at $165,000 after buying an additional 38,592 shares in the last quarter. Armistice Capital LLC lifted its holdings in shares of Promis Neurosciences by 39.1% during the 3rd quarter. Armistice Capital LLC now owns 2,974,518 shares of the company’s stock worth $1,264,000 after acquiring an additional 836,622 shares during the period. Finally, Ally Bridge Group NY LLC grew its stake in shares of Promis Neurosciences by 367.1% in the 3rd quarter. Ally Bridge Group NY LLC now owns 6,233,497 shares of the company’s stock valued at $2,649,000 after purchasing an additional 4,899,069 shares during the period. 50.13% of the stock is currently owned by institutional investors.

Promis Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.